Updates

Food Insecurity and the Dangers of Infant Formula Dilution

The CRL issued by the FDA to Regeneron for extended EYLEA HD dosing to 24 weeks cited no safety or efficacy concerns.

January 30th 2023

FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up

Demystifying Infant Formula

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.

October 11th 2022

ACIP votes in favor of recently FDA approved vaccines for meningococcal disease, chikungunya

April 17th 2025

Full case: 2-month-old with scalp swelling

Recommendations from the ACIP are forwarded to the director of the CDC, and if adopted, become official CDC policy.

2-month-old with scalp swelling | Image Credit: © daqota - © daqota - stock.adobe.com.

Rutva Vora, BS;Monica Guirguis, DO

April 17th 2025

FDA issues CRL for aflibercept 8 mg extended dosing for all indications

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

The CRL issued by the FDA to Regeneron for extended EYLEA HD dosing to 24 weeks cited no safety or efficacy concerns.

January 30th 2023

FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up

Demystifying Infant Formula

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.

October 11th 2022

ACIP votes in favor of recently FDA approved vaccines for meningococcal disease, chikungunya

April 17th 2025